Top Markets
#1 Islamic Coin Islamic Coin +151.55%
#2 Black Phoenix Black Phoenix +25.61%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.62%
#4 Fake World Assets Fake World Assets +16.15%
#5 Akedo Akedo +12.71%
#6 OpenEden OpenEden +12.39%
#7 clBTC clBTC +11.98%
#8 Palladium Network Palladium Network +11.96%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +11.81%
#10 Pons Pons +11.07%
Coin of the day
Islamic Coin Islamic Coin
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Bioasis Technologies Inc. Bioasis Technologies Inc.

Bioasis Technologies Inc.

BTI
Classifica tra le azioni #39945
Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused... Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused on innovating diagnostic methods and therapeutic solutions for a range of neurological conditions. The company's primary technological asset is the xB3 platform, engineered to enable the transport of medicinal compounds across the often-impenetrable blood-brain barrier. This capability is crucial for addressing central nervous system disorders, including various brain cancers, metabolic dysfunctions, and neurodegenerative illnesses. Bioasis is actively advancing its in-house pipeline with programs such as xB3-001 for brain metastases, xB3-002 for glioblastoma, and xB3-007 for neurodegenerative diseases, all designed to offer both symptomatic relief and disease-modifying benefits. The company has also established numerous strategic alliances. These include a partnership with Aposense Limited to deliver siRNA therapeutics for CNS disorders; a collaboration with Oxyrane UK Ltd. to combine the xB3 technology with Oxyrane's OxyCAT platform for enhanced enzyme replacement therapy targeting the brain; an agreement with Janssen Biotech, Inc. for the discovery, development, and commercialization of novel products leveraging the xB3 platform; and a research and licensing deal with Neuramedy Co Ltd. to develop and market an xB3-enhanced version of their antibody, Tomaralimab. Founded in 2006, Bioasis Technologies Inc. is headquartered in New Haven, Connecticut.
Prezzo delle azioni
$0.00366968
Ultima sincronizzazione: 2024-07-23
Capitalizzazione di mercato
$291.42K
Variazione (1 giorno)
-0.81%
Variazione (1 anno)
0.00%
Paese
US
Scambia Bioasis Technologies Inc. (BTI)

Categoria

Healthcare
Ricavi di Bioasis Technologies Inc. (BTI)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Bioasis Technologies Inc., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Bioasis Technologies Inc. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE